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Duchenne muscular dystrophy (DMD) is a recessive
X-linked form of muscular dystrophy, affecting around 1
in 3,600 boys, which results in muscle degeneration and
eventual death. Long before any promising drug was at
the horizon Duchenne parents came forward to organise
research meetings where they made it clear they were
willing to shoulder responsibility and contribute towards
advancing treatments and a cure. They became funders
of peer reviewed research and advocated for government
support. Some organisations started their own research
institutes others invested in extramural research, clinical
centers and industry to develop viable treatments for
DMD and BMD. Currently several potential drugs are in
phase 3 trials.
Through this experience Duchenne parents have learned
including Patient Organisations in trial design and selec-
tion of endpoints can make drug development more effi-
cient. Patients participate in clinical trials and will
ultimately be the ones to decide whether the tested drugs
are beneficial to them to an extent that EMA and FDA
allow these drugs. Hence patient input and advice is essen-
tial to develop a clinically meaningful endpoint. A clinical
meaningful endpoint is an endpoint that directly measures
how a patient feels (symptoms), functions (the ability to
perform activities in daily life), or survives. Therefore, a
primary endpoint should be a direct measure of one of
these. A primary endpoint should generally not be a mea-
sure of something that is not important to the patient [1].
Who knows better than the patients what is important to
them? It is remarkable that clinicians and industry often
don’t discuss the choice of primary outcome measures
with patient organisations in an early phase, but only after
they have already collected the data and are at the point to
discuss outcomes with regulators.
Regarding trial design, ethic committees mostly decide
about the burden and risk of participation in relation to a
certain trial design without asking the patients or patients’
organisations for their opinion. That is remarkable because
they are the ones who have to deal with the burden and
take the risk. Often researchers and regulators only look at
the burden of the medical intervention, where for many
patients other factors add much more to the total burden
of participation in a trial.
Care revolves around the people with a disease. Without
them there would be no need for research and drug devel-
opment. It is important that the needs of these groups are
the starting point for initiatives concerning them. Patients
know what it means to have this condition. It means they
will bring in a different perspective. Their questions and
needs are based on their own experiences, interests and
vision. There is a lot to gain from well utilised experience
and expertise.
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